The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Chebotareva A.D.

Russian Medical Academy of Continuous Professional Education, Moscow, Russia

Levin O.S.

Rossiĭskaia meditsinskaia akademiia poslediplomnogo obrazovaniia

Markov D.D.

Russian Medical Academy of Continuous Professional Education, Moscow, Russia

Sychev D.A.

Russian Medical Academy of Continuous Professional Education, Ministry of Health of the Russia, Moscow, Russia

Grishina E.A.

Russian Medical Academy of Continuous Professional Education, Moscow, Russia

Is it personalized treatment of dementia based on the CYP2D6 gene polymorphism possible?

Authors:

Chebotareva A.D., Levin O.S., Markov D.D., Sychev D.A., Grishina E.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(6‑2): 90‑94

DOI: 10.17116/jnevro201811806290

Read: 1876 times

Download PDF (RU)
Contact the author
Table of contents

IS IT PERSONALIZED TREATMENT OF DEMENTIA BASED ON THE CYP2D6 GENE POLYMORPHISM POSSIBLE?
IS IT PERSONALIZED TREATMENT OF DEMENTIA BASED ON THE CYP2D6 GENE POLYMORPHISM POSSIBLE?

To cite this article:

Chebotareva AD, Levin OS, Markov DD, Sychev DA, Grishina EA. Is it personalized treatment of dementia based on the CYP2D6 gene polymorphism possible? S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(6‑2):90‑94. (In Russ.)
https://doi.org/10.17116/jnevro201811806290

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Cyto­kine status of patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):5-12
The main mechanisms of deve­lopment of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):13-18
Curcumin-induced increased reti­nal fluorescence as a new method in the early diagnosis of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):19-25
Differential diagnosis of Alzheimer’s disease and vascular cognitive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):26-35
A comprehensive study of Alzheimer’s disease biomarkers in plasma and cere­brospinal fluid. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):43-53
Prospects for treating Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):54-60
Non-invasive biomarkers for early diagnosis of Alzheimer’s disease in bodily fluids. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):8-16
Nutritional care for patients with neurodegenerative diseases in the outpatient practice of a neurologist. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):76-83
The expe­rience of diagnosing Alzheimer’s disease based on the study of cere­brospinal fluid biomarkers. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):91-97
Neurobiological pote­ntial of astragaloside IV and prospects for its use in the treatment of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):7-12
Abstract:

Treatment of dementia is an urgent problem of modern neurology. Currently, four drugs are recommended to treat dementia, two of which (donepezil and galantamine) are metabolized with participation of the CYP2D6 enzyme. Genetic heterogeneity of CYP2D6 is associated with different enzyme activity, which affects the concentration of its substrates in blood and, accordingly, the clinical effect and the risk of side-effects of drugs. Objective. To genotype the single nucleotide polymorphism 1846G>A in the CYP2D6 gene and evaluate its effect on the efficacy and safety of donepezyl in the treatment of Alzheimer’s disease (AD). Material and methods. Twenty-one patients with AD were genotyped for the CYP2D6 1846G>A polymorphism, which corresponds to the most common in Caucasians allele CYP2D6*4. An effect of this polymorphism on the efficacy and safety of donepezyl was assessed. Results and Conclusion. There was no association between the CYP2D6 genotype and the efficacy of antidementia therapy (OR=0,44, 95% CI –3.0—1,38; p=0,46).

Keywords:

Alzheimer's disease; dementia; cholinesterase inhibitor; donepezyl; pharmacogenetics
CYP2D6

Authors:

Chebotareva A.D.

Russian Medical Academy of Continuous Professional Education, Moscow, Russia

Levin O.S.

Rossiĭskaia meditsinskaia akademiia poslediplomnogo obrazovaniia

Markov D.D.

Russian Medical Academy of Continuous Professional Education, Moscow, Russia

Sychev D.A.

Russian Medical Academy of Continuous Professional Education, Ministry of Health of the Russia, Moscow, Russia

Grishina E.A.

Russian Medical Academy of Continuous Professional Education, Moscow, Russia

Close metadata

References:

  1. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3(2):229-243. https://doi.org/10.1517/14622416.3.2.229
  2. Teh LK, Bertilsson L. Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. Drug Metab Pharmacokinet. 2012;27(1):55-67. https://doi.org/10.2133/dmpk.dmpk-11-rv-121
  3. Xiao T, Jiao B, Zhang W, Tang B, Shen L. Effect of the CYP2D6 and APOE Polymorphisms on the Efficacy of Donepezil in Patients with Alzheimer’s Disease: A Systematic Review and Meta-Analysis. CNS Drugs. 2016;30(10):899-907. https://doi.org/10.1007/s40263-016-0356-1
  4. Wang B, Yang LP, Zhang XZ, Huang SQ, Bartlam M, Zhou SF. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metabolism Reviews. 2009;41(4):573-643. https://doi.org/10.1080/03602530903118729
  5. Wang X, Li J, Dong G, Yue J. The endogenous substrates of brain CYP2D. European Journal of Pharmacology. 2014;724:211-218. https://doi.org/10.1016/j.ejphar.2013.12.025
  6. Mikus G, Bochner F, Eichelbaum M, Horak P, Somogyi AA, Spector S. Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism. J Pharmacol Exp Ther. 1994;268(2):546-551.
  7. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, Brockmöller J. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9(5):442-473. https://doi.org/10.1038/sj.mp.4001494
  8. Dalén P, Dahl ML, Bernal Ruiz ML, Nordin J, Bertilsson L. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther. 1998;63(4):444-452. https://doi.org/10.1016/s0009-9236(98)90040-6
  9. Morita S, Shimoda K, Someya T, Yoshimura Y, Kamijima K, Kato N. Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline. J Clin Psychopharmacol. 2000;20(2):141-149. https://doi.org/10.1097/00004714-200004000-00005
  10. Bertilsson L, Aberg-Wistedt A, Gustafsson LL, Nordin C. Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit. 1985;7(4):478-480. https://doi.org/10.1097/00007691-198512000-00021
  11. Tamminga WJ, Wemer J, Oosterhuis B, de Boer A, Vranckx S, Drenth BF, de Zeeuw RA, de Leij LF, Jonkman JH. Polymorphic drug metabolism (CYP2D6) and utilization of psychotropic drugs in hospitalised psychiatric patients: a retrospective study. Eur J Clin Pharmacol. 2003;59(1):57-64. https://doi.org/10.1007/s00228-003-0562-x
  12. Parker RB, Soberman JE. Effects of paroxetine on the pharmacokinetics and pharmacodynamics of immediate-release and extended-release metoprolol. Pharmacotherapy. 2011;31(7):630-641. https://doi.org/10.1592/phco.31.7.630
  13. Meyer RP, Gehlhaus M, Knoth R, Volk B. Expression and function of cytochrome p450 in brain drug metabolism. Curr Drug Metab. 2007;8(4):297-306. https://doi.org/10.2174/138920007780655478
  14. Chinta SJ, Pai HV, Upadhya SC, Boyd MR, Ravindranath V. Constitutive expression and localization of the major drug metabolizing enzyme, cytochrome P4502D in human brain. Brain Res Mol Brain Res. 2002;103(1-2):49-61. https://doi.org/10.1016/s0169-328x(02)00177-8
  15. Hiroi T, Imaoka S, Funae Y. Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun. 1998;249:838-843. https://doi.org/10.1006/bbrc.1998.9232
  16. Yu AM, Idle JR, Byrd LG, Krausz KW, Küpfer A, Gonzalez FJ: Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics. 2003;13:173-181. https://doi.org/10.1097/00008571-200303000-00007
  17. Berry MD. Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators. J Neurochem. 2004;90:257-271. https://doi.org/10.1111/j.1471-4159.2004.02501.x
  18. Haduch AA, Bromek E, Daniel WA. Role of brain cytochrome P450 (CYP2D) in the metabolism of monoaminergic neurotransmitters. Pharmacol Rep. 2013;65(6):1519-1528. https://doi.org/10.1016/s1734-1140(13)71513-5
  19. Miranda LF, Gomes KB, Tito PA, Silveira JN, Pianetti GA, Byrro RM, Peles PR, Pereira FH, Santos TR, Assini AG, Ribeiro VV, Moraes EN, Caramelli P. Clinical Response to Donepezil in Mild and Moderate Dementia: Relationship to Drug Plasma Concentration and CYP2D6 and APOE Genetic Polymorphisms. J Alzheimers Dis. 2017;55(2):539-549. https://doi.org/10.3233/jad-160164
  20. Miranda LF, Gomes KB, Silveira JN, Pianetti GA, Byrro RM, Peles PR, Pereira FH, Santos TR, Assini AG, Ribeiro VV, Tito PA, Matoso RO, Lima TO, Moraes EN, Caramelli P. Predictive factors of clinical response to cholinesterase inhibitors in mild and moderate Alzheimer’s disease and mixed dementia: a one-year naturalistic study. J Alzheimers Dis. 2015;45(2):609-620. https://doi.org/10.3233/JAD-142148
  21. Chianella C, Gragnaniello D, Maisano Delser P, Visentini MF, Sette E, Tola MR, Barbujani G, Fuselli S. BCHE and CYP2D6 genetic variation in Alzheimer’s disease patients treated with cholinesterase inhibitors. Eur J Clin Pharmacol. 2011;67(11):1147-1157. https://doi.org/10.1007/s00228-011-1064-x
  22. Clarke JA, Cutler M, Gong I, Schwarz UI, Freeman D, Dasgupta M. Cytochrome P450 2D6 phenotyping in an elderly population with dementia and response to galantamine in dementia: a pilot study. Am J Geriatr Pharmacother. 2011;9(4):224-233. https://doi.org/10.1016/j.amjopharm.2011.07.003
  23. Coin A, Pamio MV, Alexopoulos C, Granziera S, Groppa F, de Rosa G, Girardi A, Sergi G, Manzato E, Padrini R. Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer’s disease. Eur J Clin Pharmacol. 2016;72(6):711-717. https://doi.org/10.1007/s00228-016-2033-1
  24. Pilotto A, Franceschi M, D’Onofrio G, Bizzarro A, Mangialasche F, Cascavilla L, Paris F, Matera MG, Pilotto A, Daniele A, Mecocci P, Masullo C, Dallapiccola B, Seripa D. Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology. 2009;73(10):761-767. https://doi.org/10.1212/WNL.0b013e3181b6bbe3
  25. Albani D, Martinelli Boneschi F, Biella G, Giacalone G, Lupoli S, Clerici F, Benussi L, Ghidoni R, Galimberti D, Squitti R, Mariani S, Confaloni A, Bruno G, Mariani C, Scarpini E, Binetti G, Magnani G, Franceschi M, Forloni G. Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in Alzheimer’s disease patients. J Alzheimers Dis. 2012;30(4):745-749. https://doi.org/10.3233/JAD-2012-112123
  26. Zhong Y, Zheng X, Miao Y, Wan L, Yan H, Wang B. Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer’s disease. Am J Med Sci. 2013;345(3):222-226. https://doi.org/10.1097/MAJ.0b013e318255a8f9
  27. Lu J, Fu J, Zhong Y, Chen P, Yang Q, Zhao Y, Wan L, Guo C. The roles of apolipoprotein E3 and CYP2D6 (rs1065852) gene polymorphisms in the predictability of responses to individualized therapy with donepezil in Han Chinese patients with Alzheimer’s disease. Neurosci Lett. 2016;614:43-48. https://doi.org/10.1016/j.neulet.2015.12.062
  28. Seripa D, Bizzarro A, Pilotto A, D’onofrio G, Vecchione G, Gallo AP, Cascavilla L, Paris F, Grandone E, Mecocci P, Santini SA, Masullo C, Pilotto A. Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer’s disease. Pharmacogenet Genomics. 2011;21(4):225-230. https://doi.org/10.1097/FPC.0b013e32833f984c
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.